Suppr超能文献

对于两种阿非利卡人始祖低密度脂蛋白受体突变之一杂合的家族性高胆固醇血症患者的表型变异。

Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations.

作者信息

Kotze M J, De Villiers W J, Steyn K, Kriek J A, Marais A D, Langenhoven E, Herbert J S, Graadt Van Roggen J F, Van der Westhuyzen D R, Coetzee G A

机构信息

Department of Human Genetics, Faculty of Medicine, University of Stellenbosch, Tygerberg, South Africa.

出版信息

Arterioscler Thromb. 1993 Oct;13(10):1460-8. doi: 10.1161/01.atv.13.10.1460.

Abstract

Two common founder-related gene mutations that affect the low-density lipoprotein receptor (LDLR) are responsible for approximately 80% of familial hypercholesterolemia (FH) in South African Afrikaners. The FH Afrikaner-1 (FH1) mutation (Asp206-->Glu) in exon 4 results in defective receptors with approximately 20% of normal activity, whereas the FH Afrikaner-2 (FH2) mutation (Val408-->Met) in exon 9 completely abolishes LDLR activity (< 2% normal activity). We analyzed the contribution of these mutations and other factors on the variation of hypercholesterolemia and clinical features in Afrikaner FH heterozygotes. The type of FH mutation, plasma triglyceride levels, and age of patients each contributed significantly to the variation in hypercholesterolemia, whereas smoking status, high-density lipoprotein cholesterol levels, and gender had no influence. Although all FH heterozygotes had frank hypercholesterolemia, patients with the FH1 mutation had significantly lower cholesterol levels than those with the FH2 mutation. FH1 heterozygotes also tended to have milder clinical features. The differences between the two FH groups could not be explained by a difference in the common apolipoprotein E variants. This study demonstrates that mutational heterogeneity in the LDLR gene influences the phenotypic expression of heterozygous FH.

摘要

两种常见的与奠基者相关的基因突变会影响低密度脂蛋白受体(LDLR),在南非阿非利卡人中,约80%的家族性高胆固醇血症(FH)由这两种突变引起。第4外显子中的FH阿非利卡人-1(FH1)突变(Asp206→Glu)会导致受体功能缺陷,其活性约为正常活性的20%,而第9外显子中的FH阿非利卡人-2(FH2)突变(Val408→Met)则会完全消除LDLR活性(<正常活性的2%)。我们分析了这些突变及其他因素对阿非利卡人FH杂合子高胆固醇血症变异和临床特征的影响。FH突变类型、血浆甘油三酯水平和患者年龄对高胆固醇血症的变异均有显著贡献,而吸烟状况、高密度脂蛋白胆固醇水平和性别则无影响。尽管所有FH杂合子都有明显的高胆固醇血症,但携带FH1突变的患者胆固醇水平显著低于携带FH2突变的患者。FH1杂合子的临床特征也往往较轻。两组FH患者之间的差异无法用常见载脂蛋白E变体的差异来解释。这项研究表明,LDLR基因的突变异质性会影响杂合子FH的表型表达。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验